Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Depression in HIV/HCV Co-infected Substance Abuse Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. \>21 years~2. Speak and read English to 5th grade level of higher.~3. Eligible and ready to begin Peg-Interferon and Ribavirin (PEG-IFN/RBV) therapy for HCV at Mount Sinai's Primary Care practice or JMFC~4. HIV infected patients will need to have a CD4 count \> 100 and have demonstrated compliance to retroviral therapy~5. Not majorly depressed upon entry to study.~6. Signed informed consent to participate in CBT study~Exclusion Criteria:~1. Majorly depressed (based on administration of the PHQ-9, score considered for Major Depressive Disorder).~2. Admit to actively abusing illicit drugs or alcohol~3. Medical contraindications to a standard course of interferon/ribavirin therapy (eg: severe anemia, uncontrolled congestive heart failure)~4. Less than one year of life expectancy~5. Current participation in CBT related psychotherapy~6. Participation in any psychotherapy beginning less than 6 months before CBT sessions begin.~7. Initiated anti-depressant medication less than 6 months before CBT sessions begin~8. Severe comorbid psychiatric disease including bipolar disorder, severe personality disorder, or psychotic disorder~9. Active suicidal ideation

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CBT skills based group sessions (Type: EXPERIMENTAL): Cognitive Behavioral Therapy skills based group sessions
- Hepatitis C educational support groups (Type: ACTIVE_COMPARATOR): Hepatitis C educational support groups

Based on this trial design, predict the completion outcome and termination type (if applicable).